A prospective registry study found a greater risk for infections associated with JAK inhibitors in adolescents and adults with moderate to severe atopic dermatitis compared with biologics.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In this video, Raj Chovatiya, MD, PhD, discussed results of a study following patients with atopic dermatitis who were on lebrikizumab for 3 continuous years.

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.